DUBLIN–(BUSINESS WIRE)–The “Viral Vector Production Market Analysis by Vector Type, by Application, by Workflow, End user and by Region – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.
The viral vector production market size is estimated to be USD 673.4 million in 2021 and is expected to witness a CAGR of 22.72% during the forecast period 2022-2029. The technological breakthroughs in vector manufacturing, reliable pipeline for gene treatments and viral vector vaccinations, and highly competitive market with a variety of techniques employed by market participants are some of the key drivers for the market growth. However, issues with gene therapy and viral vectors in terms of regulation, science, and ethics are expected to restrain the market growth.
Segmentation: Viral Vector Production Market Report 2021-2029
By Vector Type (Revenue, USD Million)
Lentivirus
Retrovirus
Adeno-associated Virus (AAV)
Adenovirus
Others
By Application (Revenue, USD Million)
Biomedical Research
Vaccine Development
Cell & Gene Therapy Development
Biopharmaceutical and Pharmaceutical Discovery
By Workflow (Revenue, USD Million)
Downstream Processing
Upstream Processing
By End user (Revenue, USD Million)
Research Institutes
Pharmaceutical and Biopharmaceutical Companies
By Region (Revenue, USD Million)
North America
U.S
Canada
Europe
Germany
France
UK
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
Middle East & Africa
South Africa
GCC
Rest of MEA
Key Topics Covered:
1. Research Methodology
2. Introduction: Viral Vector Production
3. Executive Summary
4. Market Dynamics
5. Market Environment Analysis
6. COVID-19 Impact Analysis: Viral Vector Production Market
7. Market Analysis by Vector Type
8. Market Analysis by Application
9. Market Analysis by Workflow
10. Market Analysis by End user
11. Regional Market Analysis
12. North America Viral Vector Production Market
11. Europe Viral Vector Production Market
12. Asia PacificViral Vector Production Market
13. Latin America Viral Vector Production Market
14. MEAViral Vector Production Market
15. Competitor Analysis
16. Company Profiles
17. Conclusion & Recommendations
Companies Mentioned
Lonza (Switzerland)
Merck (Germany)
Oxford BioMedica (UK)
CGT Catapult (UK)
Cobra Biologics (UK)
uniQure (Netherlands)
FUJIFILM Diosynth Biotechnologies (US)
Spark Therapeutics (US).
For more information about this report visit https://www.researchandmarkets.com/r/aeh078
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
